Meagan Parrish
Lead Editor | LinkedInMeagan Parrish is the lead editor for PharmaVoice. She got her professional start as an editor at a women’s magazine in her current home of Madison, Wisconsin, before jumping into B2B industry reporting. She spent three years covering the chemicals, energy, food and healthcare sectors at numerous publications, and then became a full-time pharma journalist. During her four years as senior editor at Pharma Manufacturing, Meagan was a three-time Neal Awards finalist, and was honored to receive numerous other accolades for her industry reporting. Her highest honor was the Stephen Barr Award, a prestigious “best in show” award chosen from the 2020 pool of Gold-winning articles by the American Society of Business Publication Editors (ASBPE) for her coverage of contaminated APIs in drugs imported from overseas. Pharma Manufacturing also snagged the 2021 Magazine of the Year award from ASBPE. Meagan joined PharmaVoice in late 2021 after the publication was acquired by Industry Dive and relaunched as a daily digital. But Meagan’s most important job is being Mom to her two daughters and teaching them to cook, dance and talk in funny accents.
113 articles by Meagan Parrish
-
Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug
April 19, 2024 -
Ukraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?
April 16, 2024 -
3 big recent trial flops
April 12, 2024 -
Viral return: 3 U.S. cases concerning experts
April 5, 2024 -
After Amylyx drug failure, what’s next for ALS?
March 15, 2024 -
Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category
March 8, 2024 -
Astellas’ science chief on the leap into new technologies
Feb. 9, 2024 -
Could Novo, Lilly become first trillion-dollar healthcare companies?
Feb. 2, 2024 -
‘1 plus 1 equals 3’ — the co-CEO model in pharma
Jan. 26, 2024 -
The biggest questions hanging over pharma in 2024
Jan. 25, 2024 -
Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention
Jan. 19, 2024 -
Pharma execs sound off on trends and policies they’re tracking in 2024
Jan. 12, 2024 -
PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials
Jan. 11, 2024 -
PharmaVoice’s Crystal Ball: Perspectives on the financial future
Jan. 9, 2024 -
10 of our most read articles in 2023
Dec. 22, 2023 -
A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19
Dec. 13, 2023 -
The FDA just approved the first CRISPR drug. Here’s what’s next in gene editing.
Dec. 8, 2023 -
3 standout digital innovations in pharma this year
Dec. 1, 2023 -
A startling drop in U.S. life expectancy — and how pharma could help turn the tide
Nov. 17, 2023 -
Does BioMarin’s CEO shuffle signal bigger changes ahead?
Nov. 9, 2023 -
PharmaVoice 100s: Entrepreneurs
Nov. 3, 2023 -
Red Jacket: Helen Sabzevari, an immunotherapy pioneer
Oct. 27, 2023 -
The 2023 Red Jacket honorees
Oct. 27, 2023 -
PharmaVoice 100s: Clinical trial gurus
Oct. 19, 2023 -
5 minutes with — IDEA Pharma’s Mike Rea
Oct. 11, 2023